Search

Your search keyword '"Krug, Utz"' showing total 531 results

Search Constraints

Start Over You searched for: Author "Krug, Utz" Remove constraint Author: "Krug, Utz"
531 results on '"Krug, Utz"'

Search Results

2. Prognostic impact of CEBPA mutational subgroups in adult AML

3. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

4. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

5. Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project

6. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

7. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

9. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

10. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

11. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

12. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

13. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

14. A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia

15. Friday leukemia—a structural phenomenon

16. Prognostic impact of CEBPA mutational subgroups in adult AML

17. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

18. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

19. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia

21. P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING

22. P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?

23. P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML

24. S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

26. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

27. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

28. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

29. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

30. Prognostic impact of CEBPAmutational subgroups in adult AML

31. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

32. German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors

33. Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?

34. Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia

35. Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

36. Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

37. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

38. Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML

39. Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML

40. Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines

42. New Molecular Therapy Targets in Acute Myeloid Leukemia

43. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning

44. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

45. Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene

46. Additional file 1 of Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

47. Quality of Life and Life Satisfaction in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

48. High Prevalence of CHF and Diabetes in AML Long-Term Survivors - a Patient Forever?

49. Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

50. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms

Catalog

Books, media, physical & digital resources